| pubmed-article:12007536 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12007536 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12007536 | lifeskim:mentions | umls-concept:C0028754 | lld:lifeskim |
| pubmed-article:12007536 | lifeskim:mentions | umls-concept:C1113688 | lld:lifeskim |
| pubmed-article:12007536 | pubmed:issue | 2-3 | lld:pubmed |
| pubmed-article:12007536 | pubmed:dateCreated | 2002-5-14 | lld:pubmed |
| pubmed-article:12007536 | pubmed:abstractText | Orexin-A and -B are two peptides derived by proteolytic cleavage from a 130-amino acid precursor, prepro-orexin, which were recently isolated from the rat hypothalamus. Orexin-A is fully conserved across mammalian species, whilst rat and human orexin-B differ by two amino acids. These peptides bind to two Gq-coupled receptors, termed orexin-1 and orexin-2. The receptors are 64% homologous and highly conserved across species. Orexin-A is equipotent at orexin-1 and orexin-2 receptors, whilst orexin-B displays moderate (approximately 10 fold) selectivity for orexin-2 receptors. The distribution and pharmacology of the orexin peptides and their receptors indicate that they play a role in various regulatory systems including energy homeostasis and the regulation of feeding, the evidence for which is reviewed here. | lld:pubmed |
| pubmed-article:12007536 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12007536 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12007536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12007536 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12007536 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:12007536 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:12007536 | pubmed:author | pubmed-author:WilliamsGaret... | lld:pubmed |
| pubmed-article:12007536 | pubmed:author | pubmed-author:SmartDarrenD | lld:pubmed |
| pubmed-article:12007536 | pubmed:author | pubmed-author:ArchJonathan... | lld:pubmed |
| pubmed-article:12007536 | pubmed:author | pubmed-author:HaynesAndrea... | lld:pubmed |
| pubmed-article:12007536 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12007536 | pubmed:day | 12 | lld:pubmed |
| pubmed-article:12007536 | pubmed:volume | 440 | lld:pubmed |
| pubmed-article:12007536 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12007536 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12007536 | pubmed:pagination | 199-212 | lld:pubmed |
| pubmed-article:12007536 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:meshHeading | pubmed-meshheading:12007536... | lld:pubmed |
| pubmed-article:12007536 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12007536 | pubmed:articleTitle | Orexins and the treatment of obesity. | lld:pubmed |
| pubmed-article:12007536 | pubmed:affiliation | Neurology CEDD, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK. darren_2_smart@gsk.com | lld:pubmed |
| pubmed-article:12007536 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12007536 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12007536 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12007536 | lld:pubmed |
